NCT01577225

Brief Summary

OPSITE Post-Op Visible is a tri-layer dressing made up of a low adherent wound contact layer, lattice shaped absorbent pad and a top film that is waterproof and a bacterial barrier and is coated with a water-based adhesive. The comparator is a standard care treatment regime comprising tape and gauze. This study requires 100 eligible patients which will be recruited from the patients routinely see by the study investigators at each study site. Eligible patients will undergo surgery that results in a surgical wound of 27cm or less that is expected to have low or moderate levels of exudate and will have received at least one randomised study treatment. The primary objective is to compare OPOV and tape/gauze in terms of wear time per patient.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Nov 2011

Shorter than P25 for not_applicable

Geographic Reach
1 country

6 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2011

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2012

Completed
11 days until next milestone

First Submitted

Initial submission to the registry

April 12, 2012

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 13, 2012

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2012

Completed
Last Updated

April 26, 2017

Status Verified

April 1, 2013

Enrollment Period

5 months

First QC Date

April 12, 2012

Last Update Submit

April 24, 2017

Conditions

Keywords

Clean surgery

Outcome Measures

Primary Outcomes (1)

  • Average wear time per patient

    Average wear time per patient = Sum of evaluation dressing wear times for a patient/number of dressing applications

    0-14 days after surgery

Secondary Outcomes (14)

  • Dressing wear time

    0-14 days after surgery

  • Infection

    0-30 days after surgery

  • Clinical signs of infection

    0-30 days after surgery

  • Dehiscence

    0-14 days after surgery

  • Exudate management

    0-14 days after surgery

  • +9 more secondary outcomes

Study Arms (2)

OPSITE Post-Op Visible

EXPERIMENTAL

Subject is randomized to OPSITE Post-Op Visible group or Tape\&Gauze group. Dressing should be used right after surgery and changed as needed.

Device: OPSITE POST-OP VISIBLE

Tape&Gauze

ACTIVE COMPARATOR

Subject is randomized to OPSITE Post-Op Visible group or Tape\&Gauze group. Tape and Gauze should be used right after surgery and changed as per routin practice.

Device: Tape and Gauze

Interventions

Patient will be treated with OPSITE POST-OP VISIBLE dressing up to 14 days post surgery

OPSITE Post-Op Visible

Patient will be treated with tape and gauze up to 14 days post surgery

Tape&Gauze

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients undergoing "clean surgery" in an operating room
  • Patients whose wounds will be closed surgically and not left to heal by secondary intention.
  • Patients who are in-patients and are expected to be so for at least 5 days or are willing to return to the site for dressing changes.
  • Patients who are at least 18 years of age.Patients who understand the trial and are willing to consent to the trial
  • Patients who are willing to attend the post-discharge follow-up assessment.
  • Patients whose wounds are up to 27cm in length (as measured from end to end in a straight line)
  • Patients whose wounds are expected to have low to moderate exudate.

You may not qualify if:

  • Pregnant or lactating females
  • Patients undergoing chemotherapy, radiation therapy or taking any medication which is known to adversely affect wound healing
  • Patients with a known medical condition or status known to delay or prevent normal wound healing such as diabetes, HIV, collagen vascular disorders and primary immune disorders
  • Patients with a known sensitivity to any components of the investigational products or other similar dressings/products
  • Patients with a history of poor compliance with medical treatment
  • Patients who have participated in the study and who healed or were withdrawn.
  • Patients who are unable to understand the aims and objectives of the trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (6)

The First Affiliated Hospital, Sun Yat-Sen University

Guangzhou, Guangdong, 510080, China

Location

West China Hospital of Sichuan University

Chengdu, Sichuan, 610041, China

Location

Beijing Jishuitan Hospital

Beijing, 100035, China

Location

Peking Union Medical College Hospital

Beijing, 100730, China

Location

Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, 200092, China

Location

Shanghai Sixth People's Hospital

Shanghai, 200233, China

Location

Study Officials

  • Bingfang Zeng

    Shanghai 6th People's Hospital

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 12, 2012

First Posted

April 13, 2012

Study Start

November 1, 2011

Primary Completion

April 1, 2012

Study Completion

August 1, 2012

Last Updated

April 26, 2017

Record last verified: 2013-04

Data Sharing

IPD Sharing
Will not share

Locations